|
JO3425B1
(ar)
|
2013-07-15 |
2019-10-20 |
Novartis Ag |
مشتقات البابيريدينيل-اندول واستخدامها كعامل متمم لمثبطات b
|
|
AR106018A1
(es)
|
2015-08-26 |
2017-12-06 |
Achillion Pharmaceuticals Inc |
Compuestos de arilo, heteroarilo y heterocíclicos para el tratamiento de trastornos médicos
|
|
WO2017035408A1
(en)
|
2015-08-26 |
2017-03-02 |
Achillion Pharmaceuticals, Inc. |
Compounds for treatment of immune and inflammatory disorders
|
|
WO2017223243A1
(en)
*
|
2016-06-21 |
2017-12-28 |
X4 Pharmaceuticals, Inc. |
Cxcr4 inhibitors and uses thereof
|
|
ES2870920T3
(es)
|
2016-06-21 |
2021-10-28 |
X4 Pharmaceuticals Inc |
Inhibidores de CXCR4 y usos de los mismos
|
|
RU2018145364A
(ru)
*
|
2016-06-27 |
2020-07-28 |
Ачиллион Фармасьютикалс, Инк. |
Хиназолиновые и индольные соединения для лечения медицинских нарушений
|
|
CN113277985B
(zh)
*
|
2016-07-20 |
2023-07-28 |
纳莹(上海)生物科技有限公司 |
一种荧光探针及其制备方法和用途
|
|
CN110603252A
(zh)
|
2017-03-01 |
2019-12-20 |
艾其林医药公司 |
用于治疗医学障碍的芳基、杂芳基和杂环药物化合物
|
|
HRP20240485T1
(hr)
|
2017-08-24 |
2024-07-05 |
Novo Nordisk A/S |
Pripravci glp-1 i njihova upotreba
|
|
SI3675854T1
(sl)
|
2017-08-31 |
2025-05-30 |
Novartis Ag |
Derivati piperidinil-indola za uporabo v zdravljenju glomerulopatije c3
|
|
CA3106124A1
(en)
|
2018-07-16 |
2020-01-23 |
Novartis Ag |
Chemical process for preparing phenylpiperidinyl indole derivatives
|
|
WO2020041301A1
(en)
|
2018-08-20 |
2020-02-27 |
Achillion Pharmaceuticals, Inc. |
Pharmaceutical compounds for the treatment of complement factor d medical disorders
|
|
WO2020051532A2
(en)
|
2018-09-06 |
2020-03-12 |
Achillion Pharmaceuticals, Inc. |
Macrocyclic compounds for the treatment of medical disorders
|
|
US11814363B2
(en)
|
2018-09-06 |
2023-11-14 |
Achillion Pharmaceuticals, Inc. |
Morphic forms of danicopan
|
|
BR112021005506A2
(pt)
|
2018-09-25 |
2021-06-15 |
Achillion Pharmaceuticals, Inc. |
formas mórficas de inibidores de fator complementar d
|
|
US20220117949A1
(en)
|
2019-01-11 |
2022-04-21 |
Novartis Ag |
Lta4h inhibitors for the treatment of hidradenitis suppurativa
|
|
WO2020144605A1
(en)
|
2019-01-11 |
2020-07-16 |
Novartis Ag |
Anti-cd40 antibodies for use in treatment of hidradenitis suppurativa
|
|
PE20230819A1
(es)
|
2020-02-18 |
2023-05-19 |
Novo Nordisk As |
Composiciones y usos de glp-1
|
|
WO2021168320A1
(en)
|
2020-02-20 |
2021-08-26 |
Achillion Pharmaceuticals, Inc. |
Heteroaryl compounds for treatment of complement factor d mediated disorders
|
|
TW202504893A
(zh)
|
2020-05-18 |
2025-02-01 |
瑞士商諾華公司 |
Lnp023之結晶形式
|
|
EP4181922A1
(en)
|
2020-07-16 |
2023-05-24 |
Novartis AG |
Methods of using factor b inhibitors
|
|
US11951101B2
(en)
|
2020-07-16 |
2024-04-09 |
Novartis Ag |
Methods of using factor B inhibitors
|
|
EP4194449A4
(en)
*
|
2020-08-07 |
2024-03-20 |
Shanghai Meiyue Biotech Development Co., Ltd. |
Heterocyclic compound, preparation method therefor and use thereof
|
|
CN114057758A
(zh)
|
2020-08-07 |
2022-02-18 |
上海美悦生物科技发展有限公司 |
补体因子b抑制剂及其药物组合物、制备方法和用途
|
|
WO2022066774A1
(en)
|
2020-09-23 |
2022-03-31 |
Achillion Pharmaceuticals, Inc. |
Pharmaceutical compounds for the treatment of complement mediated disorders
|
|
WO2022143845A1
(zh)
*
|
2020-12-30 |
2022-07-07 |
江苏恒瑞医药股份有限公司 |
含氮桥杂环化合物、其制备方法及其在医药上的应用
|
|
WO2022143940A1
(zh)
*
|
2020-12-30 |
2022-07-07 |
南京明德新药研发有限公司 |
一系列哌啶取代的苯酸类化合物及其应用
|
|
CN116848238A
(zh)
*
|
2021-01-14 |
2023-10-03 |
阿雷克森制药公司 |
大环补体因子b抑制剂
|
|
US20240217953A1
(en)
*
|
2021-04-16 |
2024-07-04 |
Chia Tai Tianqing Pharmaceutical Group Co., Ltd. |
Bicyclic substituted aromatic carboxylic acid compounds
|
|
EP4333845A1
(en)
*
|
2021-05-07 |
2024-03-13 |
Novartis AG |
Iptacopan for the treatment of atypical hemolytic uremic syndrome
|
|
US20240287034A1
(en)
*
|
2021-06-03 |
2024-08-29 |
Chinook Therapeutics, Inc. |
Substituted indole compounds and methods of use thereof
|
|
WO2022264101A1
(en)
|
2021-06-18 |
2022-12-22 |
Novartis Ag |
Method of treating an autoimmune hematological disorder
|
|
US20240360103A1
(en)
*
|
2021-06-30 |
2024-10-31 |
Apellis Pharmaceuticals, Inc. |
Complement inhibition
|
|
JP2024532847A
(ja)
|
2021-08-18 |
2024-09-10 |
シーザン ハイスーク ファーマシューティカル カンパニー リミテッド |
ベンズアゼピン芳香環誘導体及びその医薬的な応用
|
|
WO2023037218A1
(en)
|
2021-09-07 |
2023-03-16 |
Novartis Ag |
Use of factor b inhibitors for the treatment of age-related macular degeneration
|
|
US20250243186A1
(en)
*
|
2021-10-27 |
2025-07-31 |
Hansoh Bio Llc |
Piperidinyl indole derivatives, preparation methods and medicinal uses thereof
|
|
CA3247772A1
(en)
|
2022-01-24 |
2023-07-27 |
Novartis Ag |
Spirocyclic piperidinyl derivatives as complement factor B inhibitors and their uses
|
|
CA3242815A1
(en)
*
|
2022-01-26 |
2023-08-03 |
Shanghai Meiyue Biotech Development Co., Ltd. |
Salt type and crystal form of complement factor b inhibitor, and preparation method therefor and application thereof
|
|
TW202342048A
(zh)
|
2022-02-28 |
2023-11-01 |
瑞士商諾華公司 |
使用ｌｏｕ０６４治療化膿性汗腺炎之方法
|
|
CA3248808A1
(en)
|
2022-03-04 |
2023-09-07 |
Novartis Ag |
USE OF IPTACOPAN FOR THE TREATMENT OF LUPUS NEPHROPATHY
|
|
CN119137099A
(zh)
|
2022-04-01 |
2024-12-13 |
诺华股份有限公司 |
补体因子b抑制剂及其用途
|
|
CN119698414A
(zh)
*
|
2022-06-20 |
2025-03-25 |
深圳信立泰药业股份有限公司 |
一种吲哚-苯基哌啶化合物及其制备方法与应用
|
|
WO2023246870A1
(zh)
*
|
2022-06-23 |
2023-12-28 |
上海济煜医药科技有限公司 |
吲哚化合物的制备、应用及用途
|
|
JP7849520B2
(ja)
*
|
2022-06-30 |
2026-04-21 |
江▲蘇▼恒瑞医▲薬▼股▲フン▼有限公司 |
含窒素架橋複素環誘導体の薬学的に許容される塩、結晶形及びその調製方法
|
|
CN117327070A
(zh)
*
|
2022-06-30 |
2024-01-02 |
江苏恒瑞医药股份有限公司 |
一种含氮桥杂环衍生物的晶型及其制备方法
|
|
US20260055107A1
(en)
*
|
2022-08-29 |
2026-02-26 |
Cms Research & Development Pte. Ltd. |
Series of nitrogen-containing bridged heterocyclic compounds and preparation method therefor
|
|
WO2024049977A1
(en)
*
|
2022-08-31 |
2024-03-07 |
Chinook Therapeutics, Inc. |
Substituted indole compounds and methods of use thereof
|
|
CA3266935A1
(en)
|
2022-09-10 |
2024-03-14 |
Jiangsu Hansoh Pharmaceutical Group Co., Ltd. |
Piperidine derivatives substituted at position 2, their preparation methods and medicinal uses
|
|
EP4617266A1
(en)
|
2022-11-11 |
2025-09-17 |
Shanghai Yisheng Biopharmaceutical company Limited |
Piperidine-substituted benzoic acid compound, and pharmaceutical composition and use thereof
|
|
TW202434558A
(zh)
*
|
2022-11-14 |
2024-09-01 |
美商奇努克醫療股份有限公司 |
補體因子ｂ抑制劑之固體形式
|
|
WO2024114677A1
(zh)
*
|
2022-11-29 |
2024-06-06 |
上海济煜医药科技有限公司 |
苯并螺环吲哚化合物的制备、应用及用途
|
|
JP2026502231A
(ja)
*
|
2022-12-31 |
2026-01-21 |
チューハイ ユナイテッド ラボラトリーズ シーオー．，エルティーディー． |
補体因子ｂ阻害剤、その医薬組成物および使用
|
|
WO2024148274A1
(en)
*
|
2023-01-05 |
2024-07-11 |
Apellis Pharmaceuticals, Inc. |
Complement inhibition
|
|
CN120731075A
(zh)
*
|
2023-02-22 |
2025-09-30 |
海思科医药集团股份有限公司 |
一种苯并氮杂芳环衍生物的药物组合物及其在医药上的应用
|
|
EP4669321A1
(en)
|
2023-02-23 |
2025-12-31 |
Novartis AG |
METHODS OF USING FACTOR B INHIBITORS
|
|
WO2024193575A1
(zh)
*
|
2023-03-21 |
2024-09-26 |
上海美悦生物科技发展有限公司 |
螺环类化合物及其药物组合物、制备方法和用途
|
|
KR20260004425A
(ko)
|
2023-04-27 |
2026-01-08 |
상하이 한서 바이오메디컬 컴퍼니 리미티드 |
피페리딜인돌 화합물의 염 및 이의 제조 방법
|
|
IL325760A
(en)
|
2023-07-04 |
2026-03-01 |
Sitala Bio Ltd |
History of 2-(1H-indol-4-yl)methyl)-isoindoline as factor B inhibitors
|
|
IL325759A
(en)
|
2023-07-04 |
2026-03-01 |
Sitala Bio Ltd |
History of 2-(1H-indol-4-yl)methyl)2H-indazole as factor B inhibitors
|
|
WO2025008517A1
(en)
|
2023-07-06 |
2025-01-09 |
Sitala Bio Ltd |
Indole derivatives with factor b inhibitory activity
|
|
WO2025008516A2
(en)
|
2023-07-06 |
2025-01-09 |
Sitala Bio Ltd |
Novel compounds
|
|
CN119371402A
(zh)
*
|
2023-07-26 |
2025-01-28 |
上海美悦生物科技发展有限公司 |
螺环烯基类或氮杂烯基类化合物及其药物组合物、制备方法和用途
|
|
CN121712505A
(zh)
|
2023-08-25 |
2026-03-20 |
诺华股份有限公司 |
使用因子b抑制剂的方法
|
|
CN121925409A
(zh)
|
2023-09-29 |
2026-04-24 |
诺华股份有限公司 |
补体因子b抑制剂及其用途
|
|
WO2025083621A1
(en)
|
2023-10-20 |
2025-04-24 |
Novartis Ag |
Treatment of hidradenitis suppurativa using anti-baff-r antibodies
|
|
WO2025119266A1
(zh)
*
|
2023-12-05 |
2025-06-12 |
西藏海思科制药有限公司 |
苯并氮杂芳环衍生物在治疗补体因子b介导的疾病中的用途
|
|
WO2025148628A1
(zh)
*
|
2024-01-10 |
2025-07-17 |
河北以岭医药研究院有限公司 |
哌啶基吲哚衍生物及其制备方法和应用
|
|
WO2025172535A1
(en)
|
2024-02-15 |
2025-08-21 |
Sitala Bio Ltd |
Indole and benzimidazole compounds as factor b inhibitors
|
|
WO2025172910A1
(en)
|
2024-02-16 |
2025-08-21 |
Novartis Ag |
Factor b inhibitors for treatment of anca-associated vasculitis
|
|
WO2025185734A1
(zh)
*
|
2024-03-08 |
2025-09-12 |
江苏豪森药业集团有限公司 |
一种多元螺环化合物的盐及其晶型、其制备方法和医药用途
|
|
CN121532400A
(zh)
*
|
2024-05-11 |
2026-02-13 |
礼邦医药(香港)有限公司 |
补体因子b抑制剂
|
|
WO2025252133A1
(zh)
*
|
2024-06-07 |
2025-12-11 |
润尔眼科药物（广州）有限公司 |
一种含吲哚基团的化合物及其用途
|
|
WO2025256647A1
(zh)
*
|
2024-06-14 |
2025-12-18 |
润尔眼科药物（广州）有限公司 |
化合物及其医药用途
|
|
WO2026002007A1
(zh)
*
|
2024-06-25 |
2026-01-02 |
珠海联邦制药股份有限公司 |
补体因子b抑制剂及其药物组合物和应用
|
|
WO2026003809A1
(en)
*
|
2024-06-29 |
2026-01-02 |
Assia Chemical Industries Ltd. |
Solid state forms of iptacopan hydrochloride
|
|
WO2026008074A1
(zh)
*
|
2024-07-05 |
2026-01-08 |
南京正大天晴制药有限公司 |
补体因子b抑制剂的晶型、其制备方法及用途
|
|
WO2026069246A1
(en)
|
2024-09-30 |
2026-04-02 |
Novartis Ag |
Complement factor b inhibitors and uses thereof
|